Oscar Health, Inc. (OSCR) shares are soaring 5.01% in Friday's intraday trading, following a price target upgrade from UBS. The healthcare insurance technology company's stock climbed despite mixed signals from the financial services firm.

UBS analysts raised their price target on Oscar Health to $12 from $11, representing a notable increase in their valuation of the company. This adjustment appears to have sparked investor optimism, driving the stock's significant upward movement. However, in an intriguing twist, UBS maintained its Sell rating on Oscar Health shares, suggesting a complex outlook for the company.

The conflicting nature of UBS's analysis – raising the price target while keeping a Sell rating – presents an interesting scenario for investors. It implies that while UBS sees increased short-term value in Oscar Health, they may have concerns about the company's long-term prospects or current valuation. As the trading day progresses, market participants will likely continue to weigh these contrasting signals, potentially leading to further volatility in Oscar Health's stock price.